Anemoside B4
(Synonyms: 白头翁皂甙B4,Chinensioside A; Pulchinenoside C; Pulchinenoside B4) 目录号 : GN10363
Anemoside B4是中药白头翁的主要活性成分，具有抗炎和抗肿瘤活性。
Cas No.:129741-57-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Anemoside B4 is the active component of Pulsatilla chinensis and possesses potential anti-inflammatory and anti-cancer properties[1]. Anemoside B4 improves cardiac function after myocardial infarction by regulating the HTR2A/ERK pathway[2]. Anemoside B4 has been widely used in dairy cows to alleviate mastitis symptoms, reduce pro-inflammatory cytokines and regulate pathogenic bacteria[3].
In vitro, Anemoside B4 treatment for 4h decreased the copy of SARS-CoV-2 with an IC50 value of 34.18 ± 2.59µM in HPAEpiC cells [4]. Anemoside B4 treatment for 6 days significantly inhibited receptor activator of nuclear factor κB ligand (RANKL)-induced differentiation of mouse bone marrow macrophages into osteoclasts with an IC50 value of 10μM[5]. Treatment of Raw 264.7 cells with 1mg/ml Anemoside B4 for 24 hours significantly inhibited cell viability, induced cell apoptosis, and decreased TLR4 protein expression[6].
In vivo, Anemoside B4 treatment via intraperitoneal injection (5mg/kg; twice a day) for 8 weeks significantly reduced blood glucose and triglyceride levels and alleviated kidney damage in diabetic rats[7]. Oral administration of Anemoside B4 (200mg/kg/day) daily for 18 days reduced disease severity and inhibited inflammation and demyelination in the spinal cord of experimental autoimmune encephalomyelitis (EAE) mice[8].
References:
[1] Li Y, Zou M, Han Q, et al. Therapeutic potential of triterpenoid saponin anemoside B4 from Pulsatilla chinensis[J]. Pharmacological Research, 2020, 160: 105079.
[2] Lv M, Sun Q, Yu Y, et al. Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway[J]. International Immunopharmacology, 2025, 164: 115394.
[3] Shen L, Shen Y, Zhang Y, et al. Effects of anemoside B4 on plasma metabolites in cows with clinical mastitis[J]. Veterinary Sciences, 2023, 10(7): 437.
[4] Xiao M, Luo R, Liang Q, et al. Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo[J]. Chinese Herbal Medicines, 2024, 16(1): 106-112.
[5] Cao Z, Niu X, Wang M, et al. Anemoside B4 attenuates RANKL-induced osteoclastogenesis by upregulating Nrf2 and dampens ovariectomy-induced bone loss[J]. Biomedicine & Pharmacotherapy, 2023, 167: 115454.
[6] Ma H, Zhou M, Duan W, et al. Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-κB/MAPK signaling pathway[J]. International Immunopharmacology, 2020, 87: 106794.
[7] Luan H, Ning L, Zheng-Xia Z, et al. Anemoside B4 Alleviates the Development of Diabetic Nephropathy In Vitro and In Vivo[J]. Revista Brasileira de Farmacognosia, 2021, 31(3): 310-321.
[8] Zou M, Chen F, Deng L, et al. Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota[J]. European Journal of Pharmacology, 2022, 931: 175185.
Anemoside B4是中药白头翁的主要活性成分，具有抗炎和抗肿瘤活性[1]。Anemoside B4可通过调控HTR2A/ERK信号通路改善心肌梗死后的心脏功能[2]。Anemoside B4已广泛应用于奶牛乳腺炎的治疗，能有效缓解临床症状、降低促炎细胞因子水平及调控致病菌[3]。
在体外，Anemoside B4处理人肺腺上皮细胞4小时可抑制SARS-CoV-2病毒复制，IC50值为34.18±2.59µM[4]。Anemoside B4处理小鼠骨髓巨噬细胞6天能显著抑制receptor activator of nuclear factor κB ligand (RANKL)诱导的破骨细胞分化，IC50值为10μM[5]。用1mg/ml浓度的Anemoside B4处理Raw 264.7细胞24小时可显著抑制细胞活力、诱导细胞凋亡并降低TLR4蛋白表达[6]。
在体内，糖尿病大鼠经腹腔注射Anemoside B4（5mg/kg；每日两次）连续8周后，血糖和甘油三酯水平显著降低，肾脏损伤得到改善[7]。实验性自身免疫性脑脊髓炎（EAE）小鼠每日口服Anemoside B4（200mg/kg/day）连续18天，可减轻疾病严重程度，并抑制脊髓炎症反应和脱髓鞘病变[8]。
| Cell experiment [1]: | |
Cell lines | Raw 264.7 cells |
Preparation Method | Raw 264.7 cells were cultured in high-glucose DMEM medium supplemented with 10% fetal bovine serum in a humidified incubator at 37°C with 5% CO2. Raw264.7 cells in the logarithmic growth phase were diluted into a 2×104/ml suspension in DMEM medium containing 10%FBS, and 100ml was seeded in 96-well plates. The normal control group and the model group were replaced with fresh serum-containing medium, and the Anemoside B4 group was added with serum-containing medium containing different concentrations of Anemoside B4 (final concentrations were 1μg/ml, 10μg/ml, 100μg/ml, and 1mg/ml, respectively) for 24 hours. Six parallel wells were set in each group. 10μl CCK-8 solution was added to each well, and the 96-well plates were incubated in an incubator for 1 to 4h before the OD value was finally determined. |
Reaction Conditions | 1μg/ml, 10μg/ml, 100μg/ml, and 1mg/ml; 24h |
Applications | Anemoside B4 treatment inhibited the growth of Raw 264.7 cells when the dose was more than 100μg/ml. |
| Animal experiment [2]: | |
Animal models | Male C57BL/6 mice |
Preparation Method | C57BL/6J mice (male, 18-22g) were housed in a sterile standard environment, drinking and eating ad libitum, and air was filtered (22±2℃, 12h light/12h dark). C57BL/6 mice were given 3% (w/v) dextran sulfate sodium (DSS) by gavage for 7 consecutive days and recovery for 1 day to establish a mouse colitis model. The mice were randomly divided into the following three groups (12 mice in each group): normal group, DSS group, and Anemoside B4 (20mg/kg) group. Anemoside B4 was intraperitoneally injected at a dose of 20mg/kg twice daily for 8 days. Mice were weighed daily during the experiment, and colon tissues were collected for analysis on the last day. |
Dosage form | 20mg/kg; twice a day for 8 days; i.p. |
Applications | Anemoside B4 treatment ameliorated the symptoms of DSS-induced colitis and alleviated the weight loss and colon length shortening in mice. |
References: | |
| Cas No. | 129741-57-7 | SDF | |
| 别名 | 白头翁皂甙B4,Chinensioside A; Pulchinenoside C; Pulchinenoside B4 | ||
| 化学名 | Chinensioside A; Pulchinenoside C; Pulchinenoside B4 | ||
| Canonical SMILES | C=C([C@]([C@@]12[H])([H])CC[C@]2(C(O[C@@]3([H])[C@@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO[C@@]4([H])[C@@](O)([H])[C@](O)([H])[C@@](O[C@@]5([H])[C@@](O)([H])[C@@](O)([H])[C@](O)([H])[C@](O5)([H])C)([H])[C@@](O4)([H])CO)=O)CC[C@@]6([C@]1([H])CC[ | ||
| 分子式 | C59H96O26 | 分子量 | 1221.38 |
| 溶解度 | DMSO: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 818.7 μL | 4.0937 mL | 8.1875 mL |
| 5 mM | 163.7 μL | 818.7 μL | 1.6375 mL |
| 10 mM | 81.9 μL | 409.4 μL | 818.7 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet